Daré Bioscience Enters into Agreement to Acquire Microchips Biotech Including Its First-in-Class Wireless, User-Controlled Drug Delivery Platform
November 11, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARÉ), a leader in women’s health innovation, today announced it entered into an agreement to acquire privately-held...
Daré Bioscience to Host Third Quarter 2019 Financial Results and Company Update Conference Call and Webcast
November 07, 2019 08:30 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...
Daré Bioscience Announces Presentation of Two Posters at American Association of Pharmaceutical Scientists 2019 PharmSci 360
October 31, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it will be presenting findings from two nonclinical...
Daré Bioscience and Strategic Science & Technologies Announce Presentation of Positive Findings from Thermography Clinical Study of Sildenafil Cream, 3.6 % in Healthy Women at the Sexual Medicine Society of North America Conference
October 28, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based...
Daré Bioscience to Participate in Two Upcoming Investor Conferences
October 14, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, its President and Chief Executive...
Daré Bioscience Announces a Poster Presentation on a Pharmacokinetic Study of DARE-FRT1, in Development for Sustained-Release Progesterone Therapy for Pregnancy Maintenance, at the American Society for Reproductive Medicine 2019 Scientific Congress & Expo
October 10, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced a poster presentation at the American Society for...
Daré Bioscience to Present an Overview on its Intravaginal Ring (IVR) Technology in Development for Sustained-Release Hormone Therapy and Pregnancy Maintenance at the 9th Annual Partnership Opportunities in Drug Delivery Conference
October 07, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that David Friend, Ph.D., its Chief Scientific Officer, will...
Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-VVA1, a Novel Application of Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy, in the International Journal of Pharmaceutics
September 11, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the article entitled “Vaginal tamoxifen for treatment of...
Daré Bioscience Announces Completion of its Content Validity Study to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
September 09, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based...
Daré Bioscience to Present at the H.C. Wainwright 21st Annual Global Investment Conference
September 04, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive...